Hexima’s Chief Executive Officer, Dr Nicole van der Weerden and Chief Science Officer, Professor Marilyn Anderson, presented Hexima’s Plant Defensin technology at the International Society for Human and Animal Mycology (ISHAM) congress in Amsterdam this week. The conference is an opportunity to showcase the benefits of Hexima’s technology and the initiation of our first clinical trials for fungal nail infections (onychomycosis).  Senior researchers Dr Kathy Parisi and Dr Mark Bleackley also presented work relating to Hexima’s antifungal technology.

Copies of the posters can be found below:

Interactions with fungal cell wall polysaccharides determines the salt tolerance of antifungal plant defensins (pdf)
M Bleackley (2018)

The plant defensin HXP124 has the potential to be a new safe and effective topical treatment for onychomycosis (pdf)
N van der Weerden (2018)

Barcode sequencing of the yeast deletion collection to define the antifungal mechanisms of plant defensins (pdf)
K Parisi (2018)